Axon Enterprise (NASDAQ:AXON) Stock Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Axon Enterprise, Inc NASDAQ: AXON. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Axon Enterprise stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock traded up $25.75 during trading on Friday, reaching $735.01. 654,601 shares of the stock traded hands, compared to its average volume of 627,317. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The company has a market capitalization of $57.22 billion, a price-to-earnings ratio of 177.54, a P/E/G ratio of 81.93 and a beta of 1.29. Axon Enterprise, Inc has a 52-week low of $279.02 and a 52-week high of $830.21. The business has a fifty day simple moving average of $763.82 and a two-hundred day simple moving average of $650.93.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business's revenue was up 31.3% on a year-over-year basis. During the same period last year, the company posted $1.15 EPS. Sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on AXON shares. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the stock an "overweight" rating in a research report on Friday, July 11th. Wolfe Research assumed coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They issued an "outperform" rating for the company. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Bank of America lifted their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Finally, Needham & Company LLC increased their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $772.08.

Institutional Investors Weigh In On Axon Enterprise

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LaSalle St. Investment Advisors LLC raised its holdings in shares of Axon Enterprise by 2.1% during the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock worth $408,000 after acquiring an additional 16 shares during the period. Hemington Wealth Management raised its stake in shares of Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 17 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Axon Enterprise by 5.0% during the 1st quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company's stock worth $203,000 after purchasing an additional 18 shares during the period. Pinion Investment Advisors LLC lifted its stake in Axon Enterprise by 3.0% during the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 19 shares in the last quarter. Finally, Kentucky Retirement Systems lifted its stake in Axon Enterprise by 0.4% during the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock worth $2,605,000 after purchasing an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Insiders Place Their Bets

In other news, CAO Jennifer H. Mak sold 75 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the sale, the chief accounting officer owned 15,240 shares of the company's stock, valued at approximately $11,762,384.40. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joshua Isner sold 905 shares of the business's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total value of $702,632.95. Following the transaction, the president directly owned 268,735 shares of the company's stock, valued at $208,643,166.65. The trade was a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 34,642 shares of company stock valued at $25,090,528. Insiders own 4.40% of the company's stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.